Search Results
Showing Results for dry eye disease
The FDA has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, a novel prescription eye drop developed by Alcon, for the treatment of both the signs and symptoms of the condition.
We are delighted to share the latest issue of touchREVIEWS in Ophthalmology, showcasing a diverse range of articles that highlight the innovation, interdisciplinary collaboration and continued advances driving progress in eye care today. We begin this issue with an important ...
During the WCC IX congress, Prof. Elisabeth Cohen, Department of Ophthalmology at NYU Grossman School of Medicine, delivered a presentation on the Management of Zoster Keratitis. In the following Q&A, she shares her clinical insights on diagnosis, treatment strategies, and prevention of this complex and often under-recognized condition.
In this Q&A, Dr Zhu shares the personal and professional influences that shaped her journey, her excitement for the future of ophthalmology, and her advice for aspiring medical professionals looking to enter the field.
The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part ...
Thermoreceptors on the ocular surface play a critical role in the development of dry eye disease (DED). An experimental eye drop called AR-15512, which activates cooling receptors, has been found to provide fast and continuous relief from dry eye symptoms, ...
The American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, held this year in San Diego, has once again showcased the latest and most exciting advancements in the field of ophthalmology. Bringing together top experts, researchers and practitioners, this year's meeting was a hub of innovation and knowledge-sharing. Among the many insightful presentations and cutting-edge technologies, a few developments stood out as particularly noteworthy. In this article, we highlight some of the most exciting breakthroughs from ASCRS 2024 that could shape the future of eye care.
We are pleased to present the latest edition of touchREVIEWS in Ophthalmology. In this issue, we offer a series of engaging editorials, in-depth review articles and insightful original research highlighting some of the latest breakthroughs, innovations and practical insights in ...
Age-related macular degeneration (AMD) is a chronic deterioration and dysfunction of the outer retinal tissue and Bruch’s membrane (BrM). It is the leading cause of vision loss in people older than 60 years and is estimated to affect 288 million people ...
Dry eye disease (DED) is a prevalent ocular condition characterized by discomfort, visual disturbances and tear film instability due to insufficient tear production or rapid tear evaporation.1 With an increasing global incidence (i.e. up to 50%) and its significant impact ...
Thyroid eye disease (TED) is an autoimmune condition that can lead to significant visual impairment, facial disfigurement and decreased quality of life. It affects 16 out of every 100,000 females and 2.9 out of every 100,000 males. Risk factors for TED include age, female ...
Welcome to the latest edition of touchREVIEWS in Ophthalmology, and my first as the journal’s Editor-in-Chief. In this issue, we are delighted to present a series of compelling articles providing insights into some of the cutting-edge developments in this ...
Retinal pharmacotherapy encompasses various drug delivery routes that offer potential avenues for effective treatment (Figure 1). Among these, intravitreal injections have emerged as the predominant method employed in clinical practice.1 They have established themselves as the primary approach for administering anti-vascular ...
The term ‘artificial intelligence’ was coined by a group of scientists during a workshop known as the “Dartmouth Summer Research Project on Artificial Intelligence” in 1956.1 The concept was based on the idea that “intelligent human behavior consisted in processes that ...
Mydriasis physiology Mydriasis refers to physiologic or pharmacologic pupillary dilation. Physiologic pupillary dilation occurs naturally as a response to low light and viewing objects in the distance. This process is mediated by both the iris sphincter and the iris dilator ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
